Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000360556 | SCV000338397 | pathogenic | not provided | 2016-01-25 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000360556 | SCV001228194 | pathogenic | not provided | 2024-10-01 | criteria provided, single submitter | clinical testing | This sequence change affects a donor splice site in intron 20 of the CACNA1F gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in CACNA1F are known to be pathogenic (PMID: 9662399, 11281458, 17525176, 22194652, 24124559, 26992781). This variant is not present in population databases (gnomAD no frequency). Disruption of this splice site has been observed in individuals with congenital stationary night blindness (PMID: 22183355, 28838317, 30825406). ClinVar contains an entry for this variant (Variation ID: 285396). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. |
Fulgent Genetics, |
RCV002502130 | SCV002784728 | pathogenic | Aland island eye disease; X-linked cone-rod dystrophy 3; Congenital stationary night blindness 2A | 2021-09-10 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000360556 | SCV005078813 | pathogenic | not provided | 2024-03-25 | criteria provided, single submitter | clinical testing | Canonical splice site variant predicted to result in a null allele in a gene for which loss of function is a known mechanism of disease; This variant is associated with the following publications: (PMID: 28838317, 30825406, 22183355, 33668843) |
Prevention |
RCV003417898 | SCV004116755 | pathogenic | CACNA1F-related disorder | 2024-07-22 | no assertion criteria provided | clinical testing | The CACNA1F c.2576+1G>A variant is predicted to disrupt the GT donor site and interfere with normal splicing. This variant has been reported in multiple individuals with congenital stationary night blindness (Wang et al. 2017. PubMed ID: 28838317; Zeitz et al. 2019. PubMed ID: 30825406; Lodha et al. 2012. PubMed ID: 22183355; Leahy et al. 2021. PubMed ID: 33668843). This variant is reported in 0.0014% of alleles in individuals of European (non-Finnish) descent in gnomAD. Variants that disrupt the consensus splice donor site in CACNA1F are expected to be pathogenic. This variant is interpreted as pathogenic. |